Researchers compared outcomes of patients who had suffered in- and out-of-hospital cardiac arrest, before and after the onset of the COVID-19 pandemic (16 March 2020). Between 01 January and 20 July 2020, 3026 cardiac arrests were reported to the Swedish Registry for Cardiopulmonary Resuscitation. https://youtu.be/n8g-88glR-Q Of these 3026 cardiac arrests, 1946 occurred … [Read more...] about COVID-19 and cardiac arrest, a lethal combination
Videos
Effect of Empagliflozin on exercise ability and symptoms in heart failure patients
The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms in patients with chronic heArt faiLure) trials evaluated the effect of 10 mg empagliflozin versus placebo on exercise ability in patients with heart failure. EMPERIAL-Reduced (NCT03448419) randomized 312 patients with heart failure with reduced ejection fraction (LVEF ≤ 40%) to receive either … [Read more...] about Effect of Empagliflozin on exercise ability and symptoms in heart failure patients
Superior Cardiac Outcomes with addition of SGLT2i to GLP-1RA
Atherosclerotic cardiovascular disease and heart failure occur more frequently in patients with type 2 diabetes mellitus. Therefore, the major goal of care of patients with type 2 diabetes is to reduce the incidence of these events. Both glucagon-like peptide agonists (GLP-1RA’s) and sodium-glucose co-transporter 2 inhibitors (SGLT2i’s) can independently improve glucose control … [Read more...] about Superior Cardiac Outcomes with addition of SGLT2i to GLP-1RA
ARTICA Trial: Research in Progress
The ARTICA (“Acute Rule out of non ST-segment elevation acute coronary syndrome in the (pre)hospital setting”) trial is being conducted at Radboud UMC in Nijmegen, the Netherlands. Dr. Cyril Camaro and his team started this randomized, 2-arm trial in March 2019 and plan to finish March 2022. The objective of the ARTICA trial is to assess cost-effectiveness and efficacy of … [Read more...] about ARTICA Trial: Research in Progress
SAMSON Trial: Role of nocebo effect in statin-associated muscle symptoms
The phenomenon of non-adherence to statin therapy is well known. Reasons for discontinuation include elevated hepatic or muscular enzymes, neurological symptoms, and muscular symptoms collectively referred to as statin-associated muscle symptoms (SAMS).1 SAMS seems to occur less frequently in randomized control trials than in observational studies. These results suggest that … [Read more...] about SAMSON Trial: Role of nocebo effect in statin-associated muscle symptoms